Bionano Genomics, Inc.BNGOReports Tue, Nov 10 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · bionano.com
Bionano Genomics provides optical genome mapping solutions, including its Saphyr and Stratys systems and associated consumables and software, used to detect and analyse structural variation in the genome for research and clinical laboratories.
Key ratios
FCF / Sales
-67.9%TTM
2025
-57.3%2024
-224.3%2023
-351.3%
Net margin
-106.6%TTM
2025
-92.6%
ROA
-32.6%TTM
2025
-27.7%2024
-37.4%2023
-33.2%
ROE
-83.6%TTM
2025
-66.2%2024
-170.3%2023
-134.6%
Revenue growth
10.0%TTM
2025
-7.4%2024
-14.8%2023
29.9%
Recent news
Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Track BNGO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer